Anixa Biosciences, Inc. (ANIX) EPS Estimated At $-0.15

November 11, 2018 - By Harriett Tippett

Analysts expect Anixa Biosciences, Inc. (NASDAQ:ANIX) to report $-0.15 EPS on December, 7.After having $-0.30 EPS previously, Anixa Biosciences, Inc.’s analysts see -50.00 % EPS growth. The stock decreased 2.34% or $0.09 during the last trading session, reaching $3.75. About 64,296 shares traded. Anixa Biosciences, Inc. (NASDAQ:ANIX) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

Anixa Biosciences, Inc. develops, acquires, and licenses emerging technologies in the areas of biotechnology. The company has market cap of $70.11 million. The firm develops Cchek, a platform for non-invasive blood tests for the early detection of various cancers, including breast, lung, colon, melanoma, ovarian, liver, thyroid, pancreatic, appendiceal, uterine, osteosarcoma, leiomyosarcoma, liposarcoma, vulvar, and prostate cancer. It currently has negative earnings. It also develops immuno-therapy drugs for the treatment of cancer.

More notable recent Anixa Biosciences, Inc. (NASDAQ:ANIX) news were published by: which released: “74 Biggest Movers From Friday” on November 05, 2018, also with their article: “42 Biggest Movers From Yesterday” published on October 16, 2018, published: “Anixa Biosciences (ANIX) Announces Scheduling of Pre-Sub Meeting with FDA for its Cchek Cancer” on October 24, 2018. More interesting news about Anixa Biosciences, Inc. (NASDAQ:ANIX) were released by: and their article: “Anixa Biosciences (ANIX) Files Pre-Submission, Requests Meeting with FDA Regarding Cchek” published on October 15, 2018 as well as‘s news article titled: “Anixa Bio sets meeting with FDA for marketing application for prostate cancer test” with publication date: October 24, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: